The C242T polymorphism of the NAD(P)H oxidase p22phox subunit is associated with an enhanced risk for cerebrovascular disease at a young age.

Division of Molecular and Clinical Neurobiology, Department of Psychiatry, Ludwig Maximilian University, Munich, Germany.
Cerebrovascular Diseases (Impact Factor: 2.81). 10/2008; 26(4):430-3. DOI: 10.1159/000155639
Source: PubMed

ABSTRACT Oxidative stress has been proposed as a major contributing factor for vascular disease, that acts independently from its participation in predisposing disorders such as diabetes and arterial hypertension. A functionally relevant C242T polymorphism of the CYBA gene encoding the NAD(P)H oxidase p22(phox) subunit, is supposed to lead to an abnormal reduction in the generation of reactive oxygen species in vascular smooth-muscle and endothelial cells.
We investigated the p22(phox) C242T single-nucleotide polymorphism by polymerase chain reaction in consecutive patients with ischemic stroke or transient ischemic attack under the age of 50 (n = 161) and in population-based control subjects (n = 136).
Homozygosity for the T variant was associated with an enhanced risk for cerebral ischemia (odds ratio 3.85, confidence interval 1.39-10.64) after adjusting for classical risk factors. Risk for cerebral ischemia was not increased in heterozygous subjects.
The p22(phox) C242T single-nucleotide polymorphism is associated with stroke risk. This finding supports the hypothesis that oxidative stress may contribute to stroke pathogenesis.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aging is a complex and multifactorial process that is stimulated by a number of factors including genes and life-style. It is thought that the production of reactive oxygen species (ROS) in the face of antioxidant enzymes and molecules is related to aging and age-related diseases. NAD(P)H oxidase system is the predominant cellular source of ROS, and p22phox, the major component of that system, is essential for the activation of NAD(P)H oxidase. The aim of this study was to investigate the association between p22phox C242T single nucleotide polymorphism and aging in Turkish population. Blood samples were collected from 332 volunteers between 18 and 95 years of age and were classified into three groups according to their ages as <65, 65-84 and ≥85. p22phox C242T polymorphism was genotyped by PCR-RFLP method. CC genotype frequency in the C242T polymorphism is higher in older group (≥85) than younger groups (<65 and 65-85), whereas CT + TT genotype frequency is lower in older group. When the p22phox C242T polymorphism was compared with the mean ages and age groups, statistically significant associations were found. We showed for the first time that human aging is significantly associated with p22phox C242T genotypes in Turkish population, being highest in CC, intermediate in CT, and lowest in TT homozygote. It is plausible to suggest that CC genotype might protect people from chronic inflammation, diseases as well as from oxidative stress and, thus, individuals with CC genotype might be more advantageous for aging as compared to those with CT + TT genotypes.
    Aging - Clinical and Experimental Research 08/2013; · 1.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, the wealth of basic science research supporting resveratrol's potential to treat, delay, and even prevent age-related chronic diseases has led to a number of human clinical trials. While such translational research has yielded promising results in clinical populations, recently published conflicting results from studies evaluating resveratrol's potential for primary prevention of chronic disease in healthy / asymptomatic individuals have generated considerable controversy and do not initially appear consistent with findings from animal models. We argue that trials targeting healthy humans are often fundamentally flawed owing to inappropriate use of paradigms only applicable to populations with overt clinical disease and the consequent misleading (typically negative) results can severely retard advancement of drug development. To appropriately perform translational research centered on resveratrol as a primary prevention agent in non-clinical populations, it is critical to utilize study designs which can provide adequate information on clinically relevant outcome measures, avoid paradigms and assumptions from interventions which are specific to clinical populations, and maintain realistic expectations compared to interventions which provide the theoretical maximal response (e.g., caloric restriction and aerobic exercise training).
    Aging 07/2013; 5(7):495-506. · 4.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 15-Deoxy-∆(12,14)-PGJ2 (15d-PGJ2) and thiazolidinedione attenuate reactive oxygen species (ROS) production via a peroxisome proliferator-activated receptor-gamma (PPAR-γ)-dependent pathway. Nonetheless, how PPAR-γ mediates ROS production to ameliorate ischemic brain injury is not clear. Recent studies indicated that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the major source of ROS in the vascular system. In the present study, we used an in vitro oxygen-glucose deprivation and reoxygenation (hypoxia reoxygenation [HR]) paradigm to study whether PPAR-γ interacts with NADPH oxidase, thereby regulating ROS formation in cerebral endothelial cells (CECs). With pharmacological (PPAR-γ antagonist GW9662), loss-of-function (PPAR-γ siRNA), and gain-of-function (Ad-PPAR-γ) approaches, we first demonstrated that 15d-PGJ2 protected HR-treated CECs against ROS-induced apoptosis in a PPAR-γ-dependent manner. Results of promoter and subcellular localization analyses further revealed that 15d-PGJ2, by activating PPAR-γ, blocked HR-induced NF-κB nuclear translocation, which led to inhibited transcription of the NADPH oxidase subunit p22phox. In summary, we report a novel transrepression mechanism whereby PPAR-γ downregulates hypoxia-activated p22phox transcription and the subsequent NADPH oxidase activation, ROS formation, and CEC apoptosis.
    Molecular Neurobiology 12/2013; · 5.47 Impact Factor


Available from
Jun 17, 2014